Browsing Tag

Ryvu Therapeutics

Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RVU120 at the…

Eli Pacheco Jun 9, 2023 0

Ongoing Phase 1b Dose-Escalation Study of Single-Agent Treatment with RVU120 in Patients with AML or High-Risk MDS Shows Clinical Benefit and Favorable Safety;Dose-Escalation Continues,…

Health

Ryvu Therapeutics Presents Clinical and Translational Data of RVU120 and SEL24…

Eli Pacheco Dec 11, 2022 0

RVU120 Demonstrates Single-Agent Activity with a Complete Response, 4 Blast Reductions, and 4 Erythroid and/or Platelet responses in Patients with Relapsed/Refractory Acute Myeloid Leukemia…

Health

Ryvu Therapeutics Announces Poster Presentations at the AACR-NCI-EORTC Molecular…

Eli Pacheco Oct 12, 2022 0

KRAKOW, Poland, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that…